Alveolar proteinosis in a patient recovering from Pneumocystis carinii infection : A case report with a review of literature
Petio V Kotov, Vinod B Shidham
Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
|Date of Submission||21-Apr-2006|
|Date of Acceptance||12-Oct-2006|
|Date of Web Publication||12-Oct-2006|
Petio V Kotov
Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
Source of Support: None, Conflict of Interest: None
Background: Pulmonary alveolar proteinosis is a rare lung disorder, which was first reported as idiopathic condition in 1958. The prevalence of acquired pulmonary alveolar proteinosis has been estimated to be 0.37 per 100,000 population. The cause of this condition is not entirely clear. We present alveolar proteinosis in a case recently treated for pulmonary Pneumocystis carinii infection.
Case presentation: A 25-year-old Caucasian female presented with shortness of breath during management of acute pancreatitis. She had a heart-transplant six years ago, a distal pancreatectomy secondary to pancreatitis two years ago, chronic renal failure secondary to Prograft taken for six years to suppress transplant rejection, and a more recent history of Pneumocystis carinii infection treated in the preceding 21 days with augmented doses of Bactrim (Trimethoprim, Sulfamethoxazole). She had bilateral pleural effusions with radiological and clinical features suspicious for interstitial lung disease. Cytopathologic evaluation of broncho-alveolar lavage (BAL) showed hyaline alveolar casts admixed with amorphous debris and scant chronic inflammatory cells, consistent with alveolar proteinosis. GMS and PAS stains were negative for P. carinii. Direct Fluorescent Antibody (DFA) test for P. carinii performed on the BAL specimen in our Microbiology Lab had been repeatedly negative.
Conclusion: Cytopathological findings in bronchoalveolar lavage, with clinical differential diagnosis of interstitial lung disease, were diagnostic. Pulmonary alveolar proteinosis after recent treatment for P. carinii infection suggests a relationship of pulmonary alveolar proteinosis with P. carinii infection in the immunocompromised patient.
|How to cite this article:|
Kotov PV, Shidham VB. Alveolar proteinosis in a patient recovering from Pneumocystis carinii infection : A case report with a review of literature. CytoJournal 2006;3:22
|How to cite this URL:|
Kotov PV, Shidham VB. Alveolar proteinosis in a patient recovering from Pneumocystis carinii infection : A case report with a review of literature. CytoJournal [serial online] 2006 [cited 2017 Aug 24];3:22. Available from: http://www.cytojournal.com/text.asp?2006/3/1/22/41229
| » Background|| |
Pulmonary alveolar proteinosis is an accumulation of abundant extra cellular periodic acid-Schiff (PAS) positive proteinaceous material in alveolar spaces. It was first described as an idiopathic condition in 1958 . This material represents surfactant distending the alveolar space. Papanicolaou-stained smears of bronchoalveolar lavage (BAL) fluid show characteristic hyaline globular alveolar casts which are green, or orange, or centrally orange with a green rim . The globules may show scant cells "hugging" the periphery, which appear to be imprints of the pulmonary alveoli with occasional carry-over of pneumocytes lining the alveoli. Electron microscopy demonstrates whorled myelin figures characteristic of surfactant .
| » Case presentation|| |
A 25-year-old Caucasian female with a history of heart transplant, presented with shortness of breath. Twenty one days prior to her presentation, she had P. carinii pneumonia for which she was treated with augmented doses of Bactrim (Trimethoprim, Sulfamethoxazole). She also noticed a progressive lower extremity edema, pleuritic chest pain, dry cough, and chills. She was diagnosed as chronic renal failure and was started on hemodialysis as an outpatient. During hemodialysis, she experienced abdominal pain radiating to the back. She presented to the emergency room with acute respiratory distress syndrome and acute pancreatitis secondary to a stone in the pancreatic duct. She was admitted and shortly after, she required intubation because of decreased oxygen saturation. A chest X-ray showed increased interstitial markings, suggestive of interstitial lung disease. Bilateral pleural effusions were also noted and attributed to the chronic renal failure with fluid overload. Recurrence of P. carinii infection was also considered a possibility. BAL was performed as part of a diagnostic-treatment protocol and 15 cc of cloudy pinkish fluid was sent for cytopathologic evaluation. Two Papanicolaou (PAP) stained SurePath™ preparations were prepared.
The PAP stained SurePath preparations showed characteristic globular alveolar casts of amorphous material which stained green, orange, and centrally orange with a green rim [Figure 1]. This material was PAS positive and was resistant to diastase [Figure 2]. GMS stain [Figure 3] did not show the characteristic crushed ping-pong ball like structures with central to eccentric dots [Figure 3a,b] observed in the frothy casts associated with P. carinii pneumonia [Figure 3c,d].
Oxygen saturation improved after BAL procedure. Three days later she was extubated, and was discharged within a week. Apart from a hysterectomy for severe cervical dysplasia six months after this event, she has had an uneventful healthy course. Currently she is alive and well.
| » Discussion|| |
Although pulmonary alveolar proteinosis is usually difficult to differentiate clinically and radiologically from interstitial lung disease, it can be recognized in BAL. BAL fluid in alveolar proteinosis is usually opaque on gross appearance. Proper interpretation of BAL in these cases spares the patient an open lung biopsy. This is especially important for debilitated or transplant patients, because pulmonary alveolar proteinosis may be amenable to treatment by a simple procedure such as BAL alone.
The globular alveolar casts of pulmonary alveolar proteinosis should be distinguished from foamy alveolar casts of P. carinii in BAL specimens. In alveolar proteinosis the globular structures are hyaline as compared to foamy in P. carinii. The globular extra cellular hyaline material is PAS (diastase resistant) positive [Figure 2]. The morphological details should be scrutinized under higher magnification, especially at the periphery of these casts. The foamy casts in P. carinii show distinct dark dots in individual vacuoles even in PAP stained preparations. If the details cannot be appreciated in PAP stained preparations, special stain such as GMS are helpful [Figure 3]. P. carinii organisms demonstrate characteristic crushed "ping-pong" ball-like GMS stained dark P. carinii cysts-structures in the frothy casts [Figure 3c,d]. They are not present in the hyaline casts of alveolar proteinosis [Figure 3a,b]. For further comparison of P. carinii and PAP, see [Table 1].
As demonstrated in humans and mouse models, ultrastructurally the alveolar spaces in pulmonary alveolar proteinosis show numerous lamellar bodies with a structural resemblance to myelin. These lamellar bodies are similar to the surfactant present in type II pneumocytes. It is hypothesized that hyperplasic and hypertrophic type II pneumocytes produce increased amounts of lamellar bodies and develop into mononucleated giant balloon cells . When they rupture, these mononucleated giant cells liberate numerous myelinoid structures, lipid droplets, and many electron dense amorphous acicular crystals which are closely associated with the extracellular membranous material.
Pulmonary alveolar proteinosis occurs in three clinically distinct forms: idiopathic, congenital, and secondary .
Idiopathic pulmonary alveolar proteinosis has been an enigmatic acquired disorder since its initial description . The exact etiology of this variant is not entirely clear but appears to be multifactorial, comprising the combined effect of infectious, environmental and hereditary factors.
The congenital form comprises of a heterogeneous group of disorders  caused by mutations in the genes encoding surfactant protein B or C or the ?C chain of the receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) [7-11].
Most of the studies report the congenital form of alveolar proteinosis. One possible explanation for this form revolves around surfactant. Normally, surfactant is inactivated by mechanical and biologic processes and converted into small, surface-inactive aggregates. Approximately 70 to 80 percent of the small aggregates are taken up by alveolar type II pneumocytes, transported to phagolysosomes, and reused or catabolized. Alveolar macrophages internalize and catabolize the remaining surfactant pool, a process critically dependent on GM-CSF. Some patients with alveolar proteinosis have shown to have genetic defects rendering the GM-CSF receptor ineffective. The interruption of GM-CSF signaling in the alveolar macrophage, for example, by targeted ablation of the gene encoding GM-CSF or its receptor in mice or, presumably, by neutralizing anti-GM-CSF auto antibodies in humans, causes accumulations of eosinophilic lipoproteinaceous material and large, foamy macrophages in the alveoli .
The secondary pulmonary alveolar proteinosis develops in association with conditions involving functional impairment or reduced numbers of alveolar macrophages. Such conditions include some hematologic malignancies, pharmacologic immune suppression, inhalation of inorganic dust (e.g., silica) or toxic fumes, and certain infections .
The relationship of pulmonary alveolar proteinosis with recently treated P. carinii infection has not been specifically stressed previously. However, one case from a series describing spectrum of morphological changes in alveolar spaces, associates co-trimoxazole (Trimethoprim, Sulfamethoxazole) treated P. carinii pneumonia with alveolar proteinosis. Ultra structural examination of alveoli in case number 5 of this study showed lamellar-body-like structures resembling those of alveolar proteinosis . Our case was also recently treated for P. carinii infection with Bactrim (Trimethoprim, Sulfamethoxazole, co-trimoxazole). The patient improved after BAL and was discharged.
This case suggests a link between treated P. carinii infection and pulmonary alveolar proteinosis in this immunocompromised heart transplant patient. The treated P. carinii organisms may lead to accumulation of lamellar-body-like structures in alveolar spaces with resultant alveolar proteinosis, which if diagnosed correctly could be treated with appropriate therapy including relatively simple procedure such as BAL. Similar reports have linked pulmonary alveolar proteinosis with Mycobacterium avium-intracellulare  and also with active P. carinii infection as well as other opportunistic infections . The later report also stresses the connection between immunosuppressed patients and pulmonary alveolar proteinosis.
In summary, this case highlights the importance of differentiating P. carinii infection from alveolar proteinosis with emphasis on correct differentiation of the frothy globular casts in P. carinii infection from the hyaline globular casts in alveolar proteinosis. Correct interpretation of BAL would facilitate proper management and clinical recovery. A relationship between Bactrim treated PCP and Pulmonary Alveolar Proteinosis should be considered during the management of such cases.
| » Abbreviations|| |
PAP, Papanicolaou stain; BAL, Broncho Alveolar Lavage; GMS, Grocott Methanamine Silver; GM-CSF, granulocyte-macrophage colony-stimulating factor; PAS, periodic acid-Schiff; PCP, Pneumocystis carinii pneumonia.
| » Competing interests|| |
The author(s) declare that they have no competing interests.
| » Authors' contributions|| |
PK, Cytopathology fellow, collected all the data, participated in cytological evaluation, and drafting of manuscript.
VS, Conceptual organization, cytological-histological evaluation, and manuscript review.
| » Acknowledgements|| |
- We would like to thank Dr. Basil Varkey for reviewing the manuscript and his input on the subject.
- Due to the archival nature of the case and only one patient involved as well as the absence of any potentially identifying patient information, the Institutional Review Board at the Medical College of Wisconsin, Milwaukee, did not require patient authorization for this case report.
| » References|| |
|1.||Rosen SH, Castleman B, Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med 1958, 258: 1123-1142. |
|2.||Shidham VB: Respiratory Cytology. In Atkinson Atlas of Diagnostic Cytopathology . Volume Chapter 7 . Second edition. Edited by: Atkinson BF. Philadelphia, PA: W. B. Saunders Company; 2004:273-356. |
|3.||Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Sinickas V, Dunn AR: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91 (12) : 5592-6. 1994 Jun 7 |
|4.||Murata Y, Emi Y, Denda A, Konishi Y: Ultrastructural analysis of pulmonary alveolar proteinosis induced by methylnaphthalene in mice. Exp Toxicol Pathol 1992, 44: 47-54. |
|5.||Bruce TrapnellC, Jeffrey WhitsettA, Koh Nakata: Pulmonary alveolar proteinosis. N Engl J Med 2003, 349: 2527-2539. |
|6.||Nogee LM, deMello DE, Dehner LP, Colten HR: Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993, 328: 406-410. |
|7.||Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001, 344: 573-579. |
|8.||Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, deMello DE, Colten HR: A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994, 93 (4) : 1860-3. |
|9.||Dirksen U, Nishinakamura R, Groneck P, Hattenhorst U, Nogee L, Murray R, Burdach S: Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 100 (9) : 2211-7. 1997 Nov 1 |
|10.||deMello DE, Lin Z: Pulmonary alveolar proteinosis: a review. Pediatr Pathol Mol Med 2001, 20: 413-432. |
|11.||Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, Dickersin GR, Bachurski CJ, Mark EL, Whitsett JA: Involvement of granulocyte-macrophage colony-stimulating factor in pulmonaryhomeostasis. Science 264 (5159) : 713-6. 1994 Apr 29 |
|12.||Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, Maher DW, Cebon J, Sinickas V, Dunn AR: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91 (12) : 5592-6. 1994 Jun 7 |
|13.||Maygarden SJ, Iacocca MV, Funkhouser WK, Novotny DB: Pulmonary alveolar proteinosis: a spectrum of cytologic, histochemical, and ultrastructural findings in bronchoalveolar lavage fluid. Diagn Cytopathol 2001, 24 (6) : 389-95. |
|14.||Hibiya I: Morphological changes in Pneumocystis carinii in the alveolar space due to treatment with co-trimoxazole - comparison of clinical cases and experimental rats. Kansenshogaku Zasshi 1990, 64: 455-466. |
|15.||Bakhos R, Gattuso P, Arcot C, Reddy VB: Pulmonary alveolar proteinosis: an unusual association with Mycobacterium avium-intracellulare infection and lymphocytic interstitial pneumonia. South Med J 1996, 89 (8) : 801-2. |
|16.||Bedrossian C, Luna M, Conklin R, Miller W: Alveolar proteinosis as a consequence of immunosuppression. Human Pathology 1980, 11: 527-535. |
[Figure 1], [Figure 2], [Figure 3], [Figure 3a,b], [Figure 3c,d]
|This article has been cited by|
||Up-regulation of surfactant protein production in a mouse model of secondary pulmonary alveolar proteinosis
| ||Shibasaki, M., Hashimoto, K., Okamoto, M., Hayashi, Y., Imaizumi, K., Hashimoto, N., Ozaki, N., (...), Kawabe, T. |
| ||American Journal of Respiratory Cell and Molecular Biology. 2009; 40(5): 536-542 |
||Up-Regulation of Surfactant Protein Production in a Mouse Model of Secondary Pulmonary Alveolar Proteinosis
| ||Masataka Shibasaki,Katsunori Hashimoto,Masakazu Okamoto,Yuta Hayashi,Kazuyoshi Imaizumi,Naozumi Hashimoto,Nobuaki Ozaki,Toyoharu Yokoi,Kenzo Takagi,Yoshinori Hasegawa,Kaoru Shimokata,Tsutomu Kawabe |
| ||American Journal of Respiratory Cell and Molecular Biology. 2009; 40(5): 536 |
|[Pubmed] | [DOI]|
||CytoJournalæs move to the new platform: More on financial model to the support open-access charter in cytopathology, publication quality indicators, and other issues
| ||Shidham, VB and Pitman, MB and DeMay, RM and Atkinson, BF |
| ||CytoJournal. 2008; 5(1): 15 |
||The best in CytoJournal: 2006
| ||Cohen, M.B. |
| ||CytoJournal. 2007; 4(1): 12 |
||Thank you reviewers-CytoJournal 2007
| ||Shidham, V.B. and Atkinson, B.F. |
| ||CytoJournal. 2007; 4(1): 4 |